NIDCR Science News - December 2018

Having trouble viewing this email? View it as a Web page. Bringing a Diversity of Perspectives to NIDCR Science First recipient of NIDCR diversity fellowship studies biochemistry underlying developmental disorders NIDCR • December 6, 2018   Nerve-Signaling Pathway that Drives Sustained Pain Found Harvard University • December 13, 2018   STAY CONNECTED

---

STAY CONNECTED
     

SUBSCRIBER SERVICES
Manage Subscriptions | Unsubscribe All | Subscription Help | Contact Us

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Dental and Craniofacial Research · 9000 Rockville Pike · Bethesda, MD 20892

Top 10 Cancer Currents Blog Posts of 2018

Having trouble viewing this email? View it as a Web page.

With 2018 drawing to a close, we took a look back at the Cancer Currents posts published over the last 12 months. As our coverage shows, 2018 has been a year of important advances in cancer research. Some of our most-read posts were those about new treatment options for a variety of cancers, including childhood cancers. But posts about the side effects of cancer treatment and the cost of cancer drugs also received great interest. In case you missed them when they were first posted or you want to read them again or share them with a friend, here are our top 10 most-read posts of 2018. Thank you again for your interest and support. We hope you'll continue to read the blog and encourage others to subscribe. Wishing you a happy and healthy holiday season, The Cancer Currents editorial team   Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer June 28, 2018 For people with early-stage pancreatic cancer, results from two clinical trials suggest that altering the type and timing of chemotherapy improves survival. The findings will likely change the standard of care. The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr. Judith Paice July 16, 2018 The opioid epidemic is having a significant impact on cancer patients, says Dr. Judith Paice of Northwestern University. She explains how oncologists can address concerns about opioid misuse when managing cancer pain. Can Immunotherapy Succeed Against Glioblastoma? May 24, 2018 Researchers are hopeful that, for the deadly brain cancer glioblastoma, immunotherapy might succeed where other therapies have not. Different immunotherapy approaches are being tested in clinical trials. Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer February 9, 2018 Cancer treatments known as oncolytic viruses are being tested in clinical trials, and one, T-VEC or Imlygic®, has been approved by the FDA. Research now suggests that these treatments work not only by infecting and killing tumor cells, but that they may also be a form of cancer immunotherapy. Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 A new study shows that 90% of postmenopausal women diagnosed with endometrial cancer reported vaginal bleeding before their diagnosis. Approximately 9% of women who saw a doctor for bleeding, the study showed, later received an endometrial cancer diagnosis. The Imperative of Addressing Cancer Drug Costs and Value March 15, 2018 The President's Cancer Panel has released its report, Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. The report recommends six actions to maximize the value and affordability of cancer drug treatment. Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 The investigational drug selumetinib shrank tumors in some children with a genetic syndrome called neurofibromatosis type 1 (NF1). The drug also improved symptoms related to tumors known as neurofibromas, which can cause pain, difficulty breathing or walking, and disfigurement. Gut Bacteria May Influence Effectiveness of a Type of Immunotherapy February 5, 2018 Three new studies have identified intestinal bacteria that appear to influence the response to checkpoint inhibitors. Researchers think their findings could be used to improve patients' responses to these immunotherapy drugs. Study Identifies Potential Cause of Hearing Loss from Cisplatin January 26, 2018 The chemotherapy drug cisplatin is retained in the inner ear for long periods, possibly explaining the hearing loss linked to treatment with the drug. Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer August 3, 2018 The combination of the immune checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) has been approved by FDA for the treatment of patients with metastatic colorectal cancer whose tumor cells have DNA repair defects.

 

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892

There’s Still Time to Give

unsubscribe  |    |  Visit our web site  |  Donate Autism Society 4340 East West Hwy Ste 350 Bethesda, MD 20814 United States

Less than 24 hours left to double your impact

Answers. Treatments. Cures. | Match your gift. » ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Answers. Treatments. Cures. | Match your gift. » View web version     Give to find answers. Give to find better, faster treatments. Give to find cures. No matter the reason, give to the American Cancer Society. Together, we can help save lives. MATCH MY GIFT Give to find answers. Give to find better, faster treatments. Give to find cures. No matter the reason, give to the American Cancer Society. Together, we can help save lives. MATCH MY GIFT Hcis, the campaign clock is ticking. Less than 24 hours remain for you to have your gift MATCHED, up to $50,000, to help improve – and even save – more lives. Don't miss this opportunity to DOUBLE your impact with a gift of $10 or more. Because of you, we're helping save more lives than ever before through groundbreaking research, free programs and services, and so much more. Together we can do even more in 2019: new research discoveries, new treatments, and new answers. Help us reach our goal before the new year, and your gift could be DOUBLED. MATCH your gift of $10 or more, $1-for-$1, up to $50,000. Look at how your impact could double: • $50 becomes $100 and could staff our National Cancer Information Center with more caring experts ready to talk to patients and loved ones. Give 2x MORE support. • $100 becomes $200 and could give patients a ride through our Road To Recovery® program. Give 2x MORE rides. • $150 becomes $300 and could support breakthrough cancer research. Give 2x MORE answers. And most importantly, your MATCHED gift of $10 or more, up to $50,000, helps us continue this lifesaving work. Hcis, what we are doing is working. With you by our side, we're closer than ever to new cancer treatments, innovations, and answers. We can't fight cancer without you. Donate now and a generous donor will MATCH your gift, up to $50,000. Sincerely, Your American Cancer Society P.S. If you've just recently given a gift online or in the mail, thank you so much for your support of the American Cancer Society. Imagine a world free from cancer. Help us make it a reality. About Us | Legal & Privacy Information | State Fundraising Notices | Donate This email was sent to myhcistech.healthnews360@blogger.com. If this isn't the best email address at which to reach you, please call us at 1​-​800​-​227​-​2345 to update your contact information. Staying in touch via the American Cancer Society email list is the best way we have of keeping in regular contact with supporters like you across the country and letting you know how you can help save lives and support families facing cancer. You can unsubscribe from our emails at any time. But if you leave, it will be harder for you to stay involved with the American Cancer Society and continue the lifesaving work that you've been such an important part of. The American Cancer Society is doing more to fight cancer than any other non-profit organization only because we have the support of dedicated people like you. Thank you for your commitment to save lives, celebrate lives and lead the fight for a world without cancer! You can always contact us 24 hours a day, 7 days a week, at 1​-​800​-​227​-​2345 or at cancer.org/contactus. The American Cancer Society ​ | ​ ​250 Williams Street ​ ​| ​ ​Atlanta, GA 30303 Copyright 2018 © American Cancer Society